Data for: Dose Finding Study of Pentoxifylline in Children With Cerebral Malaria (doi:10.7910/DVN/VANG2V)

View:

Part 1: Document Description
Part 2: Study Description
Part 5: Other Study-Related Materials
Entire Codebook

Data for: Dose Finding Study of Pentoxifylline in Children With Cerebral Malaria

doi:10.7910/DVN/VANG2V

Harvard Dataverse

2020-02-03

1

Olola, Christopher; Kremsner, Peter Gottfried; Winstanley, Peter A.; Wamola, Betty; Newton, Charles R.; Taylor, Terrie, 2020, "Data for: Dose Finding Study of Pentoxifylline in Children With Cerebral Malaria", https://doi.org/10.7910/DVN/VANG2V, Harvard Dataverse, V1

Data for: Dose Finding Study of Pentoxifylline in Children With Cerebral Malaria

doi:10.7910/DVN/VANG2V

Olola, Christopher (KEMRI Centre for Geographic Medicine Research (Coast), Kilifi, Kenya)

Kremsner, Peter Gottfried (Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany)

Winstanley, Peter A. (University of Liverpool, Liverpool, United Kingdom)

Wamola, Betty (KEMRI Centre for Geographic Medicine Research (Coast), Kilifi, Kenya)

Newton, Charles R. (KEMRI Centre for Geographic Medicine Research (Coast), Kilifi, Kenya)

Taylor, Terrie (Blantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi)

U01 grant AI045955

Harvard Dataverse

Olola, Christopher

Taylor, Terrie

Taylor, Terrie

2020-01-30

https://doi.org/10.7910/DVN/VANG2V

Medicine, Health and Life Sciences

<p>Pentoxifylline (PTX) affects many processes that may contribute to the pathogenesis of severe malaria and it has been shown to reduce the duration of coma in children with cerebral malaria. This pilot study was performed to assess pharmacokinetics, safety and efficacy of PTX in African children with cerebral malaria.</p> <p>Ten children admitted to the high dependency unit of the Kilifi District Hospital in Kenya with cerebral malaria (Blantyre coma score of 2 or less) received quinine plus a continuous infusion of 10 mg/kg/24 hours PTX for 72 hours. Five children were recruited as controls and received normal saline instead of PTX. Plasma samples were taken for PTX and tumour necrosis factor (TNF) levels. Blantyre Coma Score, parasitemia, hematology and vital signs were assessed 4 hourly.</p> <p>The dataset contains: <ul> <li>Demographic details of the patient, history of disease, and clinical findings (vital signs, oxygen saturation, respiratory status, Blantyre coma score recorded on admission </li> <li>Laboratory on admission included parasitaemia, full blood count and differential white cell count, glucose, blood culture, blood gas analysis, electrolytes, creatinine, lactate, and aspartate transaminase (AST). Parasite density was counted per 100 white blood cells or, for high parasitaemia, per 500 red blood cells and expressed in parasites per μL</li> </ul> <p>A detailed description of the study design is given in the study protocol and results as reported by Lell, B., Köhler, C., Wamola, B., Olola, C.H., Kivaya, E., Kokwaro, G., Wypij, D., Mithwani, S., Taylor, T.E., Kremsner, P.G. and Newton, C.R., 2010. Pentoxifylline as an adjunct therapy in children with cerebral malaria. Malaria journal, 9(1), p.368. doi: <a href="https://dx.doi.org/10.1186%2F1475-2875-9-368">10.1186/1475-2875-9-368</a>. The study is also registered on ClinicalTrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT00133393">NCT00133393</a>.

Publications based on this data collection should acknowledge this source by means of bibliographic citation.

<p>This data is licensed under the <a href="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</a> <a href="https://creativecommons.org/licenses/by/4.0/legalcode"><img src="https://i.creativecommons.org/l/by/3.0/88x31.png"> </a> </p> For more detailed information beyond the metadata and documentation provided, please contact the author(s) OR the data governance office via this email address: dgc@kemri-wellcome.org

Data and documentation are openly available. For more detailed information beyond the metadata and documentation provided, please contact the author(s) OR the data governance office via this email address: dgc@kemri-wellcome.org <ul> <li>No attempt will be made to re-identify respondents, and there will be no use of the identity of any person or establishment discovered inadvertently. Any such discovery will be reported immediately to KEMRI CGMRC. </li> <li>No attempt will be made to produce links between datasets provided in this repository and other datasets that could identify individuals. </li> <li>Any works using this data will cite the source, in line with the citation requirement provided with the dataset.</li> <li>The original collector of the data, KEMRI CGMRC, and the relevant funding agencies bear no responsibility for the data's use or interpretation or inferences based upon it.</li> </ul>

Lell, B., Köhler, C., Wamola, B., Olola, C.H., Kivaya, E., Kokwaro, G., Wypij, D., Mithwani, S., Taylor, T.E., Kremsner, P.G. and Newton, C.R., 2010. Pentoxifylline as an adjunct therapy in children with cerebral malaria. Malaria journal, 9(1), p.368

10.1186/1475-2875-9-368

Lell, B., Köhler, C., Wamola, B., Olola, C.H., Kivaya, E., Kokwaro, G., Wypij, D., Mithwani, S., Taylor, T.E., Kremsner, P.G. and Newton, C.R., 2010. Pentoxifylline as an adjunct therapy in children with cerebral malaria. Malaria journal, 9(1), p.368

Label:

SMAC_PTX_DD_Master.pdf

application/pdf

Label:

SMAC_PTX_Giriama_Consent.pdf

Text:

ICF template (Giriama)

application/pdf

Label:

SMAC_PTX_Pilot_Protocol R2001-12-27.pdf

application/pdf

Label:

SMAC_PTX_Swahili_Consent_Form.pdf

Text:

ICF template (lSwahili)

application/pdf

Label:

SMAC_PTX_Datasets.zip

Text:

De-identified datasets (csv format)

application/zip